Holen Sie sich die Stockscreener-App
41.02
0.99%
-0.41
Handel nachbörslich:
41.52
0.50
+1.22%
Schlusskurs vom Vortag:
$41.43
Offen:
$41.5
24-Stunden-Volumen:
1.44M
Relative Volume:
0.91
Marktkapitalisierung:
$3.50B
Einnahmen:
$170.10M
Nettoeinkommen (Verlust:
$-239.59M
KGV:
-14.65
EPS:
-2.8
Netto-Cashflow:
$-191.20M
1W Leistung:
+2.50%
1M Leistung:
-19.95%
6M Leistung:
-23.90%
1J Leistung:
-34.43%
1-Tages-Spanne:
$40.70
$42.09
1-Wochen-Bereich:
$38.20
$42.09
52-Wochen-Spanne:
$38.20
$91.10
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Vergleichen Sie CRSP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
41.02 | 3.50B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
How To Trade (CRSP) - Stock Traders Daily
Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know - MSN
CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Not Quite Adding Up - Simply Wall St
CRISPR Therapeutics (NASDAQ:CRSP) Upgraded by StockNews.com to Sell Rating - MarketBeat
Why Is CRISPR Therapeutics AG (CRSP) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Top 11 CRISPR Stocks to Invest In - Insider Monkey
CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 52-Week LowWhat's Next? - MarketBeat
CRISPR Therapeutics stock hits 52-week low at $39.31 By Investing.com - Investing.com Nigeria
CRISPR Therapeutics stock hits 52-week low at $39.31 - Investing.com
Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025 (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors - MSN
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $77.93 Consensus Price Target from Brokerages - MarketBeat
CRISPR Therapeutics Enters Oversold Territory (CRSP) - Nasdaq
February 2025 Options Now Available For CRISPR Therapeutics (CRSP) - Nasdaq
Gene Therapy Market Analysis,Growth, Insights and Future Outlook | Exactitude Consultancy - GlobeNewswire Inc.
Institutional investors may adopt severe steps after CRISPR Therapeutics AG's (NASDAQ:CRSP) latest 8.3% drop adds to a year losses - Yahoo Finance
Geode Capital Management LLC Increases Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
(CRSP) Trading Advice - Stock Traders Daily
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term - Yahoo Finance
Intellia Crashes 60% in a Year: How Should You Play the Stock? - Yahoo Finance
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year - Investing.com
JMP Securities Reaffirms "Market Outperform" Rating for CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Hits New 1-Year LowTime to Sell? - MarketBeat
3 Things You Need to Know if You Buy CRISPR Therapeutics Today - MSN
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Sees Significant Decline in Short Interest - MarketBeat
State Street Corp Acquires 599,304 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Sets New 1-Year LowShould You Sell? - MarketBeat
3 Things You Need To Know If You Buy CRISPR Therapeutics Today - Barchart
CRISPR Therapeutics stock hits 52-week low at $43.37 - Investing.com
Zacks Research Issues Negative Forecast for CRSP Earnings - MarketBeat
Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers? - Insider Monkey
Catherine Wood's Strategic Acquisition of CRISPR Therapeutics AG Shares - GuruFocus.com
What is William Blair's Forecast for CRSP FY2024 Earnings? - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from Chardan Capital - MarketBeat
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
CRISPR's CTX112 Cancer Therapy Shows 67% Response Rate in Clinical Trial, Earns FDA Special Status - StockTitan
XTX Topco Ltd Grows Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Main Management ETF Advisors LLC Purchases Shares of 14,744 CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
2.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):